Your session is about to expire
← Back to Search
DUOC-01 for Multiple Sclerosis (DUOC for MS Trial)
DUOC for MS Trial Summary
This trial will assess the safety of using DUOC-01 cells, expanded from donated human umbilical cord blood, to treat adults with Primary Progressive Multiple Sclerosis. There will be 20 participants enrolled and researchers will explore changes in MS assessment scores, brain MRI findings, and blood biomarkers.
DUOC for MS Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowDUOC for MS Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.DUOC for MS Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have not had a severe infection in the last 2 weeks.I have seizures that medication cannot control.I have a chronic immune system disease other than MS.I am not currently receiving treatment for another cancer, nor am I on immunosuppressants for conditions other than MS or undergoing cytotoxic chemotherapy.My disability score is between 3.0 and 6.5, and it has been stable for the last 6 months.I have not had an organ, tissue, or stem cell transplant or cell therapy in the last 3 years.I need help with breathing (ventilator support).I have a bleeding disorder.I haven't had cancer in the last 2 years, except for certain skin cancers that were fully removed.I have been diagnosed with primary progressive MS.I have a progressive neurological disorder that is not MS.I have a matching umbilical cord blood unit stored.I will continue my current disease treatments while participating in the study.I am between 18 and 65 years old.My condition has not worsened in the past 3 months.
- Group 1: DUOC-01
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is geriatric participation accepted in this research protocol?
"This research is open to anyone who is 18 years of age or older, and not yet 65."
Is DUOC-01 a risk-free option for individuals?
"Due to the limited data available on DUOC-01, Power has assigned a score of 1 to its safety rating. Phase 1 trials provide only preliminary support for both efficacy and safety."
Is recruitment currently open for this clinical trial?
"Correct. Clinicaltrials.gov indicates that this medical trial is currently recruiting participants; the initial post was published on January 24th 2021, and it has since been updated as recently as January 25th 2022. The study requires 20 patients to be enrolled at one site."
Does my profile qualify me to participate in this research?
"The qualifications for this clinical trial involve being between 18 and 65 years old, having primary progressive multiple sclerosis, and with a total of 20 participants accepted."
How many participants is this research project accommodating?
"Affirmative. As per the information held on clinicaltrials.gov, this medical experiment is currently open for recruitment which commenced on January 24th 2021 and was last updated a year later. 20 participants are required from one single location."
Share this study with friends
Copy Link
Messenger